

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MABLIFE	05/21/2013
RECEIVING PARTY DATA	
Name:	Immune Pharmaceuticals Ltd.
Street Address:	15 Abba Eben Street
City:	Herzlia
State/Country:	ISRAEL
Postal Code:	46733
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11902194
CORRESPONDENCE DATA	
Fax Number:	6468780801
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	646-878-0800
Email:	USPTO@pczlaw.com
Correspondent Name:	Pearl Cohen Zedek Latzer, LLP
Address Line 1:	1500 Broadway
Address Line 2:	12th Floor
Address Line 4:	New York, NEW YORK 10036
ATTORNEY DOCKET NUMBER:	P-76119-US
NAME OF SUBMITTER:	Dahlia Goodman
Signature:	/dg/
Date:	05/30/2013
Total Attachments: 1 source=P-76119-US-signed-assignment-M2l#page1.tif	

CH \$40.00 11902194

## CONFIRMATORY ACT

Whereas MABLIFE SAS, a company organized and existing under the laws of France, and having its head office at Genepole Campus 1, 5 rue Henri Desbruères, 91030 EVRY Cedex, France (hereafter referred to as "MABLIFE"), was the owner of the U.S. Patent Application No. 11/902,194 (hereafter referred to as "the Patent"), filed on September 19, 2007 entitled :

"Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and the use thereof" (hereafter referred to as "the Patent")

Whereas, under the terms of a general Assignment Agreement dated APRIL 05<sup>th</sup>, 2012, MABLIFE has, for good and valuable consideration, sold, assigned and transferred all its rights on the aforesaid Patent unto the company IMMUNE PHARMACEUTICALS LTD., (hereafter referred to as "IMMUNE PHARMA"), a company organized and existing under the laws of Israel, and having its head office at 15 Abba Eben Avenue, HERZLIA-PITUACH 46733, ISRAEL.

MABLIFE hereby confirms the assignment, effective as of the date of APRIL 05<sup>th</sup>, 2012, of the aforesaid Patent to IMMUNE PHARMA, who accepted all of MABLIFE's rights, title and interests in and to the said Patent, including MABLIFE's full rights to sue for and recover all damages recoverable from past infringements of said Patent.


In witness whereof the parties have caused this confirmatory act to be executed as of the date of execution of the general Assignment Agreement, i.e. as of APRIL 05<sup>th</sup>, 2012

For MABLIFE SAS

Signature:

Name: M. François VALLET

Title: CEO




May 21<sup>st</sup>, 2013  
MABLIFE  
GENOPOLE CAMPUS 1  
5 rue Henri Desbruères, 91030 EVRY  
Tél : 01 60 91 78 88 / Fax : 01 60 91 78 99  
SIRET B 429 112 022 - APE 7312  
contact@mablif.com

For : IMMUNE PHARMACEUTICALS LTD.

Signature:

Name: Daniel Teper

Title: CEO



PATENT

RECORDED: 05/30/2013

REEL: 030510 FRAME: 0075